## **Supplementary materials**







Figure S1 Flow diagram detailing the selection of patients included in this study.





**Figure S2** Stratification of OS and RFS curves on the basis of histopathological differentiation to examine the prognostic effects of the Ki-67 index. (A) OS curves of patients with well and moderately differentiated tumors. (B) RFS curves of patients with well and moderately differentiated tumors. (C) OS curves of patients with poorly differentiated tumors. (D) RFS curves of patients with poorly differentiated tumors.



**Figure S3** Stratified analysis according to the grade of malignancy (GOM) to examine the influence of postoperative adjuvant chemotherapy on the overall survival of patients with different GOM. (A) Patients with low-grade tumors. (B) Patients with middle-grade tumors. (C) Patients with high-grade tumors.

## Liang et al. Significance of grade of malignancy in pancreatic ductal adenocarcinoma

| TNM stages          | GOM           |        |      | P <sub>(low vs. middle)</sub> | P <sub>(middle vs. high)</sub> | P <sub>(low vs. high)</sub> |
|---------------------|---------------|--------|------|-------------------------------|--------------------------------|-----------------------------|
|                     | Low           | Middle | High |                               |                                |                             |
| Overall survival (M | IST)          |        |      |                               |                                |                             |
| Ι                   | 57.0          | 27.0   | 22.0 | 0.012                         | 0.024                          | < 0.001                     |
| II                  | 32.0          | 22.0   | 15.0 | 0.092                         | 0.014                          | 0.001                       |
| III                 | 32.0          | 16.0   | 9.0  | 0.014                         | 0.001                          | < 0.001                     |
| Recurrence-free su  | urvival (MRT) |        |      |                               |                                |                             |
| Ι                   | 32.0          | 19.0   | 11.0 | 0.109                         | 0.036                          | < 0.001                     |
| Ш                   | 24.0          | 10.0   | 8.0  | 0.024                         | 0.134                          | 0.003                       |
| III                 | 18.0          | 6.0    | 4.0  | 0.001                         | 0.004                          | < 0.001                     |

 Table S1
 Stratified survival analysis of patients with pancreatic cancer according to TNM stage, to examine the effect of the GOM on survival

MST, median survival time; MRT, median recurrence-free survival time; GOM, grade of malignancy.

**Table S2** Stratified survival analysis of patients with pancreaticcancer according to the GOM, to examine the effect of postoperativeadjuvant chemotherapy on overall survival

| aujuvant chemotherapy on overall survival |                           |                    |          |         |  |  |  |  |  |
|---|---------------------------|--------------------|----------|---------|--|--|--|--|--|
| GOM                                       | Postoperati<br>chemothera | ve adjuvant<br>apy | $\chi^2$ | Р       |  |  |  |  |  |
|   | Yes                       | No                 |          |         |  |  |  |  |  |
| Overall su<br>Low                         | rvival (MST)<br>44.0      | 34.0               | 2.694    | 0.101   |  |  |  |  |  |
| Middle                                    | 25.0                      | 17.0               | 13.199   | < 0.001 |  |  |  |  |  |
| High                                      | 17.0                      | 11.0               | 9.040    | 0.003   |  |  |  |  |  |

MST, median survival time; GOM, grade of malignancy.